Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells

Cancer Letters

Volumn 308, Issue 2, 2011, Pages 134-143

  Wohlkoenig, Christoph ^a   Leithner, Katharina ^a   Deutsch, Alexander ^a   Hrzenjak, Andelko ^a   Olschewski, Andrea ^a   Olschewski, Horst ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Apoptosis; Cisplatin; Growth rate; Hypoxia; Re oxygenation

Indexed keywords

CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BAX;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL HYPOXIA; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; GROWTH RATE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN STABILITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79959550744     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.014     Document Type: Article

References (38)

1. Arriagada R., Auperin A., Burdett S., Higgins J.P., Johnson D.H., Le Chevalier T., Le Pechoux C., Parmar M.K., Pignon J.P., Souhami R.L., Stephens R.J., Stewart L.A., Tierney J.F., Tribodet H., van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010, 375:1267-1277. NSCLC Meta-analyses Collaborative Group.
2. Chu G. Cellular responses to cisplatin. the roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 1994, 269:787-790.
3. Borst P., Rottenberg S., Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle 2008, 7:1353-1359.
4. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
5. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
6. Weinmann M., Jendrossek V., Guner D., Goecke B., Belka C. Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J. 2004, 18:1906-1908.
7. Pires I.M., Bencokova Z., Milani M., Folkes L.K., Li J.L., Stratford M.R., Harris A.L., Hammond E.M. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res. 2010, 70:925-935.
8. Kilic M., Kasperczyk H., Fulda S., Debatin K.M. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007, 26:2027-2038.
9. Sasabe E., Tatemoto Y., Li D., Yamamoto T., Osaki T. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci. 2005, 96:394-402.
10. Alvarez-Tejado M., Naranjo-Suarez S., Jimenez C., Carrera A.C., Landazuri M.O., del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J. Biol. Chem. 2001, 276:22368-22374.
11. Selvendiran K., Bratasz A., Kuppusamy M.L., Tazi M.F., Rivera B.K., Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int. J. Cancer 2009, 125:2198-2204.
12. Sermeus A., Cosse J.P., Crespin M., Mainfroid V., de Longueville F., Ninane N., Raes M., Remacle J., Michiels C. Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol. Cancer 2008, 7:27.
13. Cosse J.P., Ronvaux M., Ninane N., Raes M.J., Michiels C. Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia 2009, 11:976-986.
14. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008, 13(Suppl. 3):21-26.
15. Lee S.M., Lee C.T., Kim Y.W., Han S.K., Shim Y.S., Yoo C.G. Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett. 2006, 242:231-238.
16. Cosse J.P., Sermeus A., Vannuvel K., Ninane N., Raes M., Michiels C. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol. Cancer 2007, 6:61.
17. Giaccia A.J. Hypoxic stress proteins: survival of the fittest. Semin. Radiat. Oncol. 1996, 6:46-58.
18. Durand R.E., Raleigh J.A. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 1998, 58:3547-3550.
19. Greco O., Marples B., Joiner M.C., Scott S.D. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J. Cell. Physiol. 2003, 197:312-325.
20. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 2003, 29:297-307.
21. Wen W., Ding J., Sun W., Wu K., Ning B., Gong W., He G., Huang S., Ding X., Yin P., Chen L., Liu Q., Xie W., Wang H. Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res. 2010, 70:2010-2019.
22. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
23. Song X., Liu X., Chi W., Liu Y., Wei L., Wang X., Yu J. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother. Pharmacol. 2006, 58:776-784.
24. Skvortsova I., Skvortsov S., Haidenberger A., Devries A., Nevinny-Stickel M., Saurer M., Lukas P., Seppi T. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J. Chemother. 2004, 16:372-380.
25. Toffoli S., Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J. 2008, 275:2991-3002.
26. Carrera S., de Verdier P.J., Khan Z., Zhao B., Mahale A., Bowman K.J., Zainol M., Jones G.D., Lee S.W., Aaronson S.A., Macip S. Protection of cells in physiological oxygen tensions against DNA damage-induced apoptosis. J. Biol. Chem. 2010, 285:13658-13665.
27. Wang D., Zhu Q., Zhang X., Zhang L., He Q., Yang B. Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells. Pharmazie 2010, 65:51-56.
28. Le Q.T., Chen E., Salim A., Cao H., Kong C.S., Whyte R., Donington J., Cannon W., Wakelee H., Tibshirani R., Mitchell J.D., Richardson D., O'Byrne K.J., Koong A.C., Giaccia A.J. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin. Cancer Res. 2006, 12:1507-1514.
29. Graves E.E., Vilalta M., Cecic I.K., Erler J.T., Tran P.T., Felsher D., Sayles L., Sweet-Cordero A., Le Q.T., Giaccia A.J. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin. Cancer Res. 2010, 16:4843-4852.
30. Sanna K., Rofstad E.K. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int. J. Cancer 1994, 58:258-262.
31. Verschraagen M., Boven E., Ruijter R., van der Born K., Berkhof J., Hausheer F.H., van der Vijgh W.J. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin. Pharmacol. Ther. 2003, 74:157-169.
32. Cullen K.J., Yang Z., Schumaker L., Guo Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr. 2007, 39:43-50.
33. Fuertes M.A., Castilla J., Alonso C., Perez J.M. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 2003, 10:257-266.
34. Berndtsson M., Hagg M., Panaretakis T., Havelka A.M., Shoshan M.C., Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int. J. Cancer 2007, 120:175-180.
35. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
36. Hussein D., Estlin E.J., Dive C., Makin G.W. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol. Cancer Ther. 2006, 5:2241-2250.
37. Zhang Q.Z., Zhang Z.F., Rao J.Y., Sato J.D., Brown J., Messadi D.V., Le A.D. Treatment with siRNA and antisense oligonucleotides targeted to hif-1 alpha induced apoptosis in human tongue squamous cell carcinomas. Int. J. Cancer 2004, 111:849-857.
38. Kim M., Park S.Y., Pai H.S., Kim T.H., Billiar T.R., Seol D.W. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking bax translocation. Cancer Res. 2004, 64:4078-4081.